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1-7)
Sakaguchi and his colleagues demonstrated that transfer of BALB/c spleen cells depleted of CD25 + cells into athymic BALB/c mice caused various autoimmune diseases which could be prevented by co-transfer of CD4 + CD25 + cells. 2, 3) Prolonged in vivo depletion of CD25 + cells by administration with anti-CD25 monoclonal antibody also caused autoimmunity. 8) CD4 + CD25 + T cells were shown to be anergic to stimulation via T cell receptor (TCR), and they suppressed antigen-specific T cell proliferation when cultured with them.
6, 7) Furthermore, recently, it has been reported that the CD28/B7 costimulatory pathway is essential for the development and homeostasis of CD4 + CD25 + regulatory T cells. 9) CD4 + CD25 + T cells with a similar immunoregulatory function have been shown to be present also in humans. 10) We previously demonstrated that in vivo administration of anti-CD4 monoclonal antibody (mAb) (GK1.5) on day 6 after tumor inoculation resulted in rejection of RL male 1 tumor which grew and killed untreated BALB/c mice. The treatment induced cytotoxic T lymphocyte (CTL) generation against a dominant antigen pRL1a on RL male 1.
11)
Furthermore, we showed that in vivo administration of anti-CD25 mAb (PC61) before tumor inoculation caused rejection of some immunogenic tumors which grew and killed untreated syngeneic mice. 12) In this study, we extended those analyses and studied the relation of CD4 + and CD4 + CD25 + regulatory T cells in tumor growth. We showed that CD4 + CD25 + and putative CD4 + CD25
− regulatory cells were involved in early and late stages in tumor growth, respectively, and the occurrence of putative CD4 + CD25 − regulatory cells was dependent on CD4 + CD25 + cells. Furthermore, we studied the involvement of those regulatory T cells in tumorigenesis induced by 3-methylcholanthrene (3-MC).
MATERIALS AND METHODS
Mice BALB/c mice were purchased from Japan SLC (Shizuoka). CB-17 SCID mice were provided by Dr. Kuribayashi (Mie University School of Medicine, Mie). Tumor cells RL male 1 is a radiation-induced leukemia in a BALB/c mouse. 13) Meth A is a MC-induced fibrosarcoma in a BALB/c mouse. 14) These tumors were maintained by tissue culture and as ascites form. P1.HTR is a subline of DBA/2 MC-induced mastocytoma P815.
15)
Antibodies Anti-CD25 (IL-2Rα) mAb produced by hybridoma PC61 is a rat IgG1 antibody. 16) For in vivo administration, anti-CD25 mAb (PC61) was used after purification. The hybridoma ascites produced in CB-17 SCID mice was purified to homogeneity by ammonium sulfate precipitation, followed by chromatography on a DEAE Toyopearl 650S column (Tosoh, Tokyo). Anti-L3T4 (CD4) mAb produced by hybridoma GK1.5, provided by Dr. F. Fitch (University of Chicago, Chicago, IL), is a rat IgG2b antibody. 17) Anti-CD4 mAb (GK1.5) was used in the form of ascites.
Flow cytometry Cells (1×10
6 ) were incubated with mAb for 30 min at 4°C in 2% fetal calf serum (FCS) containing phosphate-buffered saline (PBS). Phycoerythrin (PE)-conjugated anti-CD3ε mAb (145-211), anti-CD4 mAb (GK1.5), anti-CD8α mAb (53-6.7) and FITC-conjugated anti-CD25 mAb (7D4) were used. These mAbs were purchased from PharMingen (San Diego, CA). After incubation with mAb, the cells were washed, and analyzed on a FACScan (Becton Dickinson, Mountain View, CA). In vitro generation of CTL Spleen cells (5×10 7 ) were cultured with 5×10 6 mitomycin C (MMC)-treated stimulator cells in tissue culture flasks (25 100, Corning Glass, Corning, NY) at 37°C in a 5% CO 2 atmosphere for 7 days. The cells were treated with MMC at a concentration of 50 µg/ml at 37°C for 30 min. The culture medium was RPMI 1640 supplemented with 10% heat-inactivated FCS, 2 mM glutamine, 100 U/ml penicillin, 100 µg/ml streptomycin, and 50 µM 2-ME (2-mercaptoethanol). Cell-mediated cytotoxicity assay Tumor cells (2×10 6 ) were labeled with 2 MBq of Na 2 51 CrO 4 (New England Nuclear, Boston, MA) by incubation for 1.5 h at 37°C in a 5% CO 2 atmosphere. For peptide pulsing, 5×10
−6 M pRL1a peptide 18, 19) was added to 2×10 6 labeled P1.HTR cells. After incubation for 1 h, the cells were washed and used as target cells. In assays, 5×10 3 labeled target cells (100 µl) were incubated with effector cell suspension (100 µl). After incubation for 4 h at 37°C in a 5% CO 2 atmosphere, the supernatants (100 µl) were removed and their radioactivity was measured. The percentage of specific lysis was calculated as follows: ((a−c)/(c−b))×100, where a is the radioactivity of the supernatant from target cells mixed with effector cells, b is that of the supernatant from the target cells incubated alone, and c is that of the supernatant after lysis of the target cells with 1% Nonidet P-40. Antibody administration The mice were anesthetized with ether, and mAb diluted in PBS (0.2 ml) was injected through the retrobulbar venous plexus. Induction of tumors by 3-MC 3-MC (Sigma, St. Louis, MI) was dissolved in peanut oil at a concentration of 250 µg/ml and injected subcutaneously. Tumor assay Tumor cells were injected intradermally into the mice with a 27-gauge needle. Before inoculation of the tumor cells, the hair was cut with clippers. The diameter of the tumors was measured with vernier calipers twice at right angles to calculate the mean diameter.
RESULTS
Effect of in vivo administration of anti-CD4 mAb (GK1.5) and anti-CD25 mAb (PC61) on RL male 1 and Meth A tumor growth in BALB/c mice The effect of in vivo administration of anti-CD4 mAb (GK1.5) and anti-CD25 mAb (PC61) on tumor growth was investigated after inoculation of RL male 1 and Meth A into the back of BALB/c mice. As shown in Fig. 1 , the administration of anti-CD4 mAb (GK1.5) on day 6 but not day −4 caused rejection of either RL male 1 or Meth A. On the other hand, the administration of anti-CD25 mAb (PC61) on day −4 but not day 6 resulted in rejection of the same tumors.
We further investigated the effect of anti-CD25 mAb (PC61) administered before or after tumor inoculation by sequential inoculation of different tumors at opposite flanks in a single mouse. BALB/c mice were inoculated with RL male 1 or Meth A as the first tumor, and treated with anti-CD25 mAb (PC61) on day 6, and then inoculated with Meth A or RL male 1, respectively, on day 10 as the second tumor, and the tumor growth was observed. As shown in Fig. 2 , anti-CD25 mAb (PC61) had no effect on growth of the first tumor inoculated before the treatment with anti-CD25 mAb (PC61), and caused rejection of the second tumor inoculated after the treatment with anti-CD25 mAb (PC61). 
DISCUSSION
In this study, we showed that two phenotypically different regulatory T cells were involved in different stages of tumor growth in BALB/c mice. Treatment of BALB/c mice with anti-CD25 mAb (PC61), but not anti-CD4 mAb (GK1.5) before RL male 1 or Meth A inoculation caused tumor rejection. On the other hand, treatment of BALB/c mice with anti-CD4 mAb (GK1.5) but not anti-CD25 mAb (PC61) on day 6 after inoculation of the same tumors caused rejection. Treatment of the mice with anti-CD25 mAb (PC61) later than 2 days and with anti-CD4 mAb (GK1.5) earlier than 5 days after tumor inoculation showed no tumor rejection. − regulatory T cells could be generated directly from CD4 + CD25 + regulatory T cells by downregulating the CD25 expression. Alternatively, those two populations could be derived from independent lineages of T cell differentiation. Although putative CD4 + CD25 − regulatory T cells appeared to be present in the late stage of tumor growth, those T cells may also be present in the early stage of tumor growth as a small population. In the early stage of tumor growth, CD4 + helper T cells were necessary for generating effector T cells. Depletion of CD4 + T cells by the administration of anti-CD4 mAb (GK1.5) before inoculation of the immunogenic tumors that were rejected in untreated mice abrogated the rejection response.
11) Treatment of the mice with anti-CD4 mAb (GK1.5) in the early stage of tumor growth depleted both CD4 + helper T cells and CD4 + regulatory T cells (if there were any), resulting in tumor growth. The experiment shown in Fig. 2 clearly indicated that putative CD4 + CD25 − regulatory cells were specific for each tumor. North and Bursuker 20) previously showed that CD4 + T cells from tumor-bearing mice specifically inhibited the effector T cell function in an adoptive transfer experiment. Although the specificity of CD4 + CD25 + regulatory cells could not be analyzed in this study, studies by others showed that those cells recognized antigens specifically and exerted the inhibitory effect in a non-specific fashion. 6, 21) Stephens and Mason 22) recently showed that regulatory T cells in the peripheral lymphoid tissues that prevented autoimmune diabetes in rats were in the fractions of both CD25 + and CD25 − subpopulations. On the other hand, those T cells in the thymus were observed only in the fraction of CD25 + T cells. Those findings are consistent with the present findings. In this study, we did not observe any autoimmune disease by histological examination 3 months after the anti-CD25 mAb (PC61) treatment. Taguchi and Takahashi 8) reported the occurrence of autoimmune disease after an in vivo administration of anti-CD25 mAb (PC61) by successive treatment over a prolonged time period (daily mAb injection for 11 days) and with a higher amount (1 mg per shot). The occurrence of autoimmune disease may be related to the severity of CD25-depletion.
The present study also demonstrated that the treatment of BALB/c mice with anti-CD25 mAb (PC61) at 4 or 6 weeks after MC inoculation retarded tumor occurrence and prolonged survival. Shankaran et al. 23) recently demon- 
